Abstract
Even though lifestyle changes are the mainstay approach to address obesity, Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are the most effective and durable treatments facing this pandemic and its associated metabolic conditions. The traditional classifications of bariatric surgeries labeled them as “restrictive,” “malabsorptive,” or “mixed” types of procedures depending on the anatomical rearrangement of each one of them. This conventional categorization of bariatric surgeries assumed that the “restrictive” procedures induce their weight loss and metabolic effects by reducing gastric content and therefore having a smaller reservoir. Similarly, the “malabsorptive” procedures were thought to induce their main energy homeostatic effects from fecal calorie loss due to intestinal malabsorption. Observational data from human subjects and several studies from rodent models of bariatric surgery showed that neither of those concepts is completely true, at least in explaining the multiple metabolic changes and the alteration in energy balance that those two surgeries induce. Rather, neuro-hormonal mechanisms have been postulated to underly the physiologic effects of those two most performed bariatric procedures. In this review, we go over the role the autonomic nervous system plays- through its parasympathetic and sympathetic branches- in regulating weight balance and glucose homeostasis after SG and RYGB.
Introduction
Obesity is associated with several co-morbidities that carry a significant burden on the healthcare system and quality of life of all affected subjects around the world. As of 2014, 13% of adults worldwide were obese, with the most affected region being the American continent, for the prevalence of obesity among adults in the United States increased from 33.7% in 2007–2008 to 42.4% in 2017–2018 (). Prediction models suggest that the prevalence of overweight condition in the United States will surpass 75% and that of obesity will be ∼50% by the year of 2030 (Wang et al., 2011). The initial and conventional approach for managing obesity involves multiple lifestyle modifications that implement changes in diet, activity and behavior. However, these measures rarely result in durable or drastic weight loss (Wadden et al., 2012). In the face of this raging epidemic, bariatric and metabolic surgery remains the most effective intervention to manage excess body weight and adiposity and it significantly improves most obesity-related morbidities with results lasting more than a decade. Needless to say, because of its invasiveness as well as short and long-term complications (though significantly improved) it is currently offered for selected patients who are morbidly obese and who meet certain specific criteria, after failing conventional therapy. Several types of bariatric surgeries including SG, RYGB, and other forms of gastric bypass, laparoscopic adjustable gastric banding, and duodenal switch with biliopancreatic diversion, are nowadays the most common surgical procedures being offered to patients with obesity (). Though RYGB was traditionally considered by many to be the gold standard weight loss procedure, SG had become the most commonly performed bariatric surgery since 2013 after its reimbursement was approved by Medicare and Medicaid in 2012 (). It has been demonstrated that sleeve and RYGB have comparable weight loss outcomes, at least in the short-term (Schauer et al., 2012).
The traditional theory which attributes “restriction” of gastric pouch to reduced caloric consumption and small intestinal bypass to decreased caloric absorption has been repetitively evaluated. It was shown that gastric pouch or sleeve size did not affect meal size or food intake reduction post-bariatric surgery (Topart et al., 2011; McCracken et al., 2018). Additionally, the amount or caloric malabsorption induced by gastric bypass was very modest and cannot explain solely or be responsible for the large amount of weight lost induced by this bariatric procedure (Odstrcil et al., 2010). On the other hand, it was previously shown that alteration in feeding behaviors, bile acid signaling and flow, gut microbiota, as well as several neuro-hormonal effects (through GLP-1, P-YY, Ghrelin, and leptin) play an important role in inducing many of the beneficial effects of bariatric surgery (le Roux et al., 2007; Stefater et al., 2012; Liou et al., 2013; Yan et al., 2014). Obesity was previously reported to be associated with an attenuated vagal tone and a selective increase in sympathetic tone activity specifically to musculoskeletal organs and peripheral arterial bed, predisposing to obesity-associated hypertension (, ; ). There is suggestive evidence that RYGB transiently activates the systemic sympathetic nervous system, leading to a subsequent relative enhancement in parasympathetic over sympathetic activity, that seemingly lasts longer (Lips et al., 2013). In addition, other studies suggested that the gut-brain communications via parasympathetic or sympathetic neuron fibers (afferent/sensory or efferent/motor) may also play a differential role in regulating metabolic effects of bariatric surgery (; ).
Both arms of the autonomic nervous system have been postulated to play a metabolic regulatory role in bariatric surgery. This review will review go over each system (sympathetic and parasympathetic) in regulating variable metabolic effects of RYGB and SG.
Introduction of Sympathetic and Parasympathetic Nerves and Their Implications in Metabolism
The autonomic neurons of the sympathetic and parasympathetic nervous system innervate multiple organs and regulate their many of their homeostatic functions. The autonomic nervous system often works in a closed-loop feedback mechanism where sensing of variable biological factors is transmitted via afferent neurons to the brain or brain stem. Subsequently, homeostatic centers or nuclei within the central nervous system process these signals and transmit response orders via efferent/motor neurons to target body organs. Both sympathetic and parasympathetic nervous systems maintain whole-body homeostasis (e.g., through their actions on circulation, energy metabolism, thermal situation, respiration, and immunity) in the face of both endogenous and exogenous perturbations ().
An earlier hypothesis postulated that weight gain in obesity is partially due to sympathetic nervous underactivity causing reduction in thermogenesis (Tremblay and Chaput, 2009). However, microneurography and regional noradrenaline spillover measurements in obese individuals have disproven this hypothesis, thus weakening the case for therapeutic use of β3-adrenergic agonists to stimulate thermogenesis (). Interestingly, weight loss, secondary to lifestyle interventions such as diet and exercise, improves sympathetic and parasympathetic heart rate variability, which is an index of autonomic control of cardiac activity. Bariatric surgery also improves HRV through weight loss which might also prevent cardiac autonomic neuropathy (CAN) in severe obesity (Williams et al., 2019).
The peripheral nervous system is also involved in direct and indirect regulation of food intake. Vagal afferent neurons in the duodenum and stomach are shown to respond to mechanical stretch by luminal nutrients while also integrating other visceral sensory information along with metabolic, signals, through neuronal projection into brain stem centers. After vagotomy, neuroendocrine signaling pathways from gut hormones, such as ghrelin, are disrupted. Although, celiac branch vagotomy performed concomitantly with RYGB in rat model resulted in a slightly lesser degrees of weight reduction compared to RYGB without vagotomy, this effect seemed to be transient (). Weight loss outcome in human subjects who had RYGB did not seem to be affected by having a vagotomy or not (Okafor et al., 2015). This data suggest that vagal contribution to RYGB-induced weight loss- if present- is already induced at time of surgery, supporting in part the Phantom satiation hypothesis by . Tracer studies showed that RYGB decreases the density of vagal sensory neurons and also activates microglia in the NTS, altering neuronal communication – and assumingly energy signaling- between the gut and the CNS (Mulla et al., 2018).
Laparoscopic Sleeve Gastrectomy and Roux-En-Y Gastric Bypass
Weight Loss
Roux-en-Y gastric bypass, traditionally considered as the gold standard weight loss procedure, has become the second most performed bariatric procedure since 2013. Laparoscopic sleeve gastrectomy (LSG) has become the most performed bariatric procedure worldwide, because of its efficacy in achieving weight loss results and improvements in obesity-associated comorbidities that are comparable to those of RYGB with lower operative and post-operative complications (Rosenthal et al., 2012; Parikh et al., 2013). In comparison with other bariatric surgeries, such as the laparoscopic RYGB, LSG is a shorter and less technically challenging procedure that involves fewer changes in gastrointestinal anatomy. Additionally, the stomach is longitudinally dissected during LSG, with lesser disruption of the distal fibers of gastric vagus, whereas the stomach is transversely transected during RYGB and both the dorsal and the ventral branches of the gastric vagus nerve are disrupted, creating damage to preganglionic efferent and afferent fibers (; Saeidi et al., 2012; ; ).
Glucose Control
Bariatric surgery, including RYGB and LSG, markedly ameliorate glycemic control and may reverse or prevent T2DM in individuals with obesity (Mingrone et al., 2015; Schauer et al., 2017; ; McTigue et al., 2020). The metabolic benefits appear to be weight independent as they occur prior to the onset of significant weight loss and are not correlated with weight loss magnitude. The exact underlying mechanisms are still unclear (Mingrone and Cummings, 2016). Multiple pathways have been proposed to be involved in the positive metabolic effects of RYGB, such as adipose function and morphology, glucose turnover in the liver, altered route and timing of food delivery to the small bowel, CNS control of metabolism and nutrient intake, as well as altered hormonal signaling (). Following RYGB, there is a marked and rapid increase in several gut hormones including glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic peptide (GIP), specifically in the postprandial state- and it is thought the incretin effect of these hormones contributes to improved glycemic control (; ). There is also data suggesting that the incretin effect of GLP-1 is not regulated through endocrine pathway via beta cells, supporting the hypothesis that GLP-1 promotes insulin secretions via paracrine and/or neurocrine action (Smith et al., 2014). Rapid delivery to the distal small bowel with ingested nutrients is thought to contribute to the increased GLP-1 response (Salehi et al., 2011). The known incretin effect of GLP-1 along with its central glucoregulatory effects (Parlevliet et al., 2010) and its energy regulatory effect on food intake (Ten Kulve et al., 2017), may partially explain improved glucose profile following RYGB.
Comparing the early weight loss-independent and later weight loss-dependent (after 1 year) glycemic controls of these surgeries, LSG and RYGB showed similar changes on glycemic control, despite lower concentrations of GLP-1 and slightly less BMI reduction following LSG (Wallenius et al., 2018). This is in line with the observation in rodents that even complete absence of GLP-1 does not attenuate the LSG-mediated effects on weight reduction and glucose metabolism (Wilson-Perez et al., 2013).
The increased profile of GLP-1 after bariatric surgeries is thought to be explained by the hind-gut theory, in which stimulation of the distal intestine resulted from rapid nutrient entry further down the gastrointestinal tract such as ileum, where most of L-cells are found (). In addition, it was suggested that intestinal adaptation following chronic exposure to rapid nutrient delivery may lead to expansion in enteroendocrine cell population or nutrient-sensing capability, which contribute to the exaggerated increase in levels of postprandial GLP-1 after LSG or RYGB. It has to be noted that this observation is more consistent with RYGB than with LSG (). Interestingly, there were studies showing that LSG may lead to augmented elevation in postprandial GLP-1 (Ramon et al., 2012; Yousseif et al., 2014) comparable to that of RYGB.
Peptide YY (PYY), an anorexigenic peptide secreted by L-cells mostly located in the ileum and colon, reduces appetite, decreases the contraction of gallbladder, slows gastric emptying, suppresses gastric and pancreatic secretion, and increases nutrient absorption in the ileum. It was demonstrated that reduced PYY secretion in obese patients significantly increases after LSG, comparable to those observed after RYGB ().
Sympathetic Nervous System and Roux-En-Y Gastric Bypass
Bariatric surgery improves metabolic abnormalities in morbidly obese individuals. Hyperlipidemia, hypertension, T2DM, and obstructive sleep apnea are improved substantially following the surgery. Although improved blood pressure following RYGB has been attributed to weight-loss, lower blood pressure can occur before the reduction of body weight (). Therefore, the blood pressure -lowering effect secondary to surgery may be weight loss independent. The potential underlying mechanisms of the blood pressure -lowering effects following RYGB include enhanced secretion of incretins, such as GLP-1 and PYY (Ochner et al., 2011), reducing leptin levels (Rodriguez et al., 2012), alerting microbiota in the GI tract (Lin et al., 2019), increasing excretion of urinary sodium (), and decreasing sympathetic nervous system activity (Zhang et al., 2014).
It is recognized that obesity is characterized by sympathetic nervous activation which contributes to hypertension associated with obesity. The time course of this change as well as the underlying mechanisms are not completely understood (Lohmeier and Iliescu, 2013). In addition, obesity and overweightness are characterized by sympathetic overactivity which mirrors the severity of the clinical condition and reflects metabolic alterations (). In the context of obesity, it has been hypothesized that increased resting sympathetic neural activity (tone) occurring following weight gain could be an adaptive mechanism to increase resting energy expenditure therefore reset the body weight back to a given set-point ().
Using microneurography to directly measure sympathetic activity, it was demonstrated that human subjects who had undergone RYGB experience a reduced systemic sympathetic tone, specifically a muscular sympathetic nerve activity contributing (MSNA) to total energy expenditure ().
Endocannabinoids, originally believed to be primarily central neuromodulators, can stimulate autonomic sympathetic pathway, regulate fat intake, and enhance energy expenditure (Quarta et al., 2010; ; ). Our recent in vivo studies with mice suggested that RYGB but not LSG increases splanchnic nerve activity, which induces thermogenesis of visceral fat and enhances resting metabolic rate (Ye et al., 2020). Furthermore, use of an endocannabinoid receptor-1 (CB1) inverse agonist, mirrors RYGB-specific effects on energy expenditure and gut’s sympathetic nerve activity. Whereas arachidonoylethanolamide, a CB1 agonist, attenuated the weight loss that was induced by RYGB. Therefore, this “browning” of visceral fat post-RYGB – which is mediated by sympathetic nerve activity- appears to be CB1 signaling dependent. Our findings suggested that CB1 plays a pivotal role in energy balance following RYGB via a pathway that the sympathetic nervous system is involved (Ye et al., 2020).
In summary, obesity seems to be associated with a state of increased sympathetic tone activity (in particular MSNA). RYGB has shown to decrease systemic sympathetic nerve activity (SNA) and likely to increase splanchnic sympathetic nerve activity, selectively, to activate thermogenesis and lipolysis of visceral white adipose tissue.
Parasympathetic Nervous System and Roux-En-Y Gastric Bypass
The vagus nerve can act on the stomach and affects weight loss. The gastric sensory input is conveyed to the CNS via gastric vagal afferents, the central terminals of which enter the brainstem via the solitary tract and synapses of neurons on the nucleus tractus solitarius (NTS) (; ; ; ). ∼70% of vagal afferents innervate the abdominal viscera, mostly the intestines and stomach (Prechtl and Powley, 1990; ; Powley and Phillips, 2002). Abdominal vagal afferent signaling is important in the regulation of food intake following gastrointestinal stimuli (Peters et al., 2005; , ). Efferent innervation to the stomach originates from the dorsal motor nucleus of the vagus (; ; Moran et al., 1997), which then projects to the myenteric plexus, terminating in the stomach with the highest density of efferent nerves (). Furthermore, NTS preganglionic neurons can control the cholinergic excitatory and non-adrenergic non-cholinergic (NANC) inhibitory postganglionic neurons (). In vivo studies showed that RYGB causes a significant reduction in the weight of rats with T2DM, augmented the concentrations of serum insulin and GLP-1. These metabolic effects following RYGB partially depend on hepatic branch of the vagus nerve, as selective vagotomy of this nerve is associated with weight regain and the relative lower levels of serum GLP-1 and insulin (Qiu et al., 2014).
found that LSG upregulated, whereas RYGB downregulated the density of the vagal afferents on the NTS in rats. In addition, RYGB, but not LSG, significantly activated microglia in the NTS. These findings suggested that RYGB, but not LSG, leads to vagal microglia activation and remodels gut-brain actions (). In line with this, it was recently demonstrated that subdiaphragmatic vagotomy can remodel central vagal afferent terminals in the NTS (Peters et al., 2013), and activate microglia in the DMV, NTS, and nodose ganglia. This microglia remains markedly activated in the DMV and nodose ganglia for 7 weeks after subdiaphragmatic vagotomy (). Based on this delineated role of the vagus nerve mediating gut function and relaying sensory input to feeding centers in the hindbrain, it was speculated that these processes are remodeled after bariatric procedure ().
Melanocortin-4 receptors (MC4R) are expressed in the hypothalamus and hindbrain as well as in autonomic neurons including parasympathetic vagal sensory neurons and preganglionic cholinergic motor neurons (parasympathetic and sympathetic). They play an important role in regulation food intake and energy expenditure in response to peripheral energy signals such as micro-nutrients or gut hormones. In line with these observations, severe obesity was found in humans with naturally occurring Mc4r mutations and mice with Mc4r-deficiency (; Vaisse et al., 1998). Moreover, MC4Rs appear to be a mechanistic connection between the digestive system, CNS, and autonomic signaling to brown adipose tissue and the abdominal viscera (Zechner et al., 2013).
Furthermore, Zechner et al. (2013) found that MC4Rs in cholinergic preganglionic vagal motor neurons mediated glucose and lipid homeostasis improvements following RYGB and this effect was weight independent. While MC4R signaling in preganglionic cholinergic motor neurons (parasympathetic and sympathetic) is crucial for the increased energy expenditure and weight loss induced by RYGB (Zechner et al., 2013). A rare variant of carriers of MC4R named I251L, was shown to have enhanced weight loss following RYGB and augmented basal activity in vitro, as well as improved early diabetes resolution following surgery that is weight-independent than non-carriers. They suggested that MC4Rs mediated autonomic efferent signaling is key to induce metabolic effects following RYGB, including these weight-independent benefits such as improved glucose profile (Zechner et al., 2013).
An endogenous agonist of the peroxisome proliferator-associated receptor-α (PPAR-α), Oleoylethanolamide (OEA), is produced by enterocytes of the upper small intestine. It was shown that OEA can activate PPAR-α receptors via vagal sensory output to suppress fat intake through striatal (Tellez et al., 2013) and hypothalamic () feeding circuits. demonstrated that RYGB stimulated lower small intestine production of OEA, and augmented lipid sensing in the gut through PPAR-α, which subsequently relayed this signal to the CNS via vagal afferents neurons. This vagal signal led to increased dorsal striatal dopamine 1 receptor (D1R) expression/and signaling (). It was suggested that fat consumption post-RYGB is dependent on local OEA, vagus nerve and dorsal striatal D1R signaling, as interfering with them reversed the metabolic benefits of RYGB on fat preferences and intake ().
Previous studies have shown a beneficial effect of weight loss primarily on measures of parasympathetic activity after RYGB (Maser et al., 2007; Perugini et al., 2010). Other studies suggested that changes in autonomic tone after RYGB could be secondary to a direct effect of weight loss (Wasmund et al., 2011). It has been previously shown that glucose homeostasis and insulin secretions could be mediated by autonomic nerve system via neurotransmitters and GI peptides, which is thought to be part of the brain-gut signaling pathway that regulate metabolic effects following RYGB. For example, insulin and glucagon release can be regulated by peptides and neurotransmitters released from neurons innervating the islets (; Sterl et al., 2016). Acetylcholine, pituitary adenylate cyclase activating polypeptide, vasoactive intestinal polypeptide, and gastrin releasing peptide released from parasympathetic neurons all enhance insulin secretion (). It was shown that patients with T2DM who underwent RYGB, and experienced rapid remission of their diabetes not only had increased actions of GI peptides, but also had increased heart rate variability, particularly the high-frequency component, suggesting an enhanced parasympathetic outflow after RYGB as it has been demonstrated previously (; ). The results support involvement of neuro-hormonal mechanisms in the rapid improvement of glucose metabolism following RYGB in T2DM. This again supports the theory of changes in autonomic nervous system activity following RYGB in modulating the metabolic effects of this surgery.
In summary, there is convincing evidence that the parasympathetic nervous system activity – represented mainly by the vagus nerve- is modulated after RYGB. This alteration in vagal tone has been tightly connected to changes in several gut hormones and early improvement in glucose metabolism post-RYGB.
Sympathetic Nervous System and Laparoscopic Sleeve Gastrectomy
Reduced vagal function and increased sympathetic activity were observed in obese subjects. The improvement in parasympathetic tone following LSG was evidenced by enhanced heart rate variability in women with obesity, as early as the first month after surgery (). LSG has shown a greater effect on the parasympathetic tone than RYGB, probably because LSG preserves the vagal trunk at the lesser curvature of stomach ().
Using high-fat diet induced obese mice underwent sham or LSG surgery and implantation of radio telemeters, McGavigan et al. (2017) found LSG decreased blood pressure in LSG-operated mice compared with both sham-operated groups (ad libitum and pair feeding), which were associated with a body weight-independent reduction in hypothalamic PERK-mediated ER stress, inflammation of hypothalamus and sympathetic nervous system tone.
The sympathetic nerve system is a key regulator in the production of leptin by white fat. Leptin production is extremely reduced in mice exposed to a cold environment, when sympathetic stimulation of white fat was enhanced. This can also occur after administration of norepinephrine and isoproterenol. Thus sympathetic nerve excitement inhibits the synthesis of leptin (Rayner and Trayhurn, 2001). In contrast, use of methyltyrosine to interfere with catecholamine synthesis can increase leptin levels in experimental animals. The sympathetic nerve system not only regulates leptin production, but also modulates its effects. In a mouse model where, sympathetic nerves are chemically removed, the original leptin effects of increased blood sugar, insulin, and glucagon were altered when exogenous leptin was given to mice (; Palmen et al., 2001). It was suggested that LSG-induced weight loss results in profound sympathoinhibitor effects, accompanied by a significant and stable attenuation in leptin levels of plasma, while the improved insulin sensitivity was decayed with time regardless (Seravalle et al., 2014).
Laparoscopic sleeve gastrectomy surgery reduces stomach capacity and removes the fundus by excising the larger curvature of the stomach, thereby reducing the level of circulating ghrelin, which is predominantly secreted from the fundus and upper gastric body. As the level of ghrelin is reduced, people are prone to feeling full and reducing food intake, thereby reducing caloric intake (). It can also increase insulin secretion to have anti-diabetogenic effects. In addition, the levels of the insulin-promoting hormone GLP-1 and the appetite-suppressing polypeptide PYY3-36 secreted by the gastrointestinal tract are increased after the operation, which promotes the secretion of insulin and increases cellular insulin sensitivity. In addition, LSG surgery regulates blood sugar and triglyceride levels, reduces the secretion of antibiotic peptides such as leptin or monocyte chemoattractant protein 1, and increases anti-inflammatory mediators such as adiponectin.
Sympathetic neuron-associated macrophages (SAMs) are subset of macrophages recently characterized and identified within the white adipose tissue and long the sympathetic fibers innervating fat cells. They express SLC6A2 transporter which is responsible for noradrenaline degradation and consequently decreasing SNS- mediated thermogenesis. SAMs have been observed to be elevated in state of obesity and eliminating them or their degradation enzyme (SCLC6A2) results in activated thermogenesis. We do not know yet, the effect of either RYGB or SG on SAMs level or activity within WAT (Larabee et al., 2020).
In summary, LSG seems to have an early systemic neuro-inhibitory sympathetic effect that might be responsible for the blood pressure, and leptin reduction effects. There is limited proof that LSG (like RYGB) can induce activation of selective autonomic sympathetic nerves or tracts (such as the splanchnic) or augment sympathetic-mediated thermogenesis.
Bariatric surgery might also change taste acuity an/or olfaction, and potentially influence food preference and caloric consumption, which in turn leads to weight loss. Heightened sensitivity to sweetness could also be altered by the increase in GLP-1, P-YY and changes in other regulators hormones (such as insulin, ghrelin and leptin) that occur post RYGB and LSG. Several gut hormones and their receptors are expressed within the taste buds themselves, suggesting a possible role in palatability in addition to their known metabolic functions (Mulla et al., 2018).
Parasympathetic Nervous System and Laparoscopic Sleeve Gastrectomy
Variable gastrointestinal signaling inputs are thought to be involved in ingestion of food, which can directly- or indirectly- activate vagal afferent nerve endings in a predominantly paracrine fashion to induce gastric relaxation, and pancreatic exocrine secretion. Circulating neurohormones such as CCK and GLP-1 act directly at the brainstem to modulate vagal afferent and efferent activity in addition to their potential actions as neurotransmitters within these neurocircuits (). One of the hypotheses regarding resolution of T2DM following bariatric procedures (specifically LSG) has been attributed to changes in gut hormone and alteration in anatomy. The rearrangement of gastrointestinal anatomy enhances simultaneous increase of GLP-1, P-YY, adiponectin and post-prandial insulin, and reduction in leptin as a result of fat mass reduction (). Other hypotheses suggest that elevated levels of bile acid, diet-induced thermogenesis, altered gut microbiome, or even changes in energy balance (due to reduction in food intake) per say leads to weight loss and consequently improvement in glucose homeostasis (Pournaras and le Roux, 2013; ). Short-term weight loss seems to be comparable between LSG and RYGB (Sjostrom et al., 2012; ; ), but long term data seems to be in favor of RYGB from the weight loss as well as from the T2DM resolution stand point (O’Brien, 2015). Medications for T2DM and hypertension were decrease or withdrawn for those undergoing bariatric surgery, as early as prior to hospital discharge (Tritsch et al., 2015). In line with this, found a 60% remission rate of T2DM after LSG that did not correlate with weight loss.
Weight loss and improved glycemic profile following LSG have been attributed to a theory denominating the “gastric hypothesis,” which asserts that alterations in the secretion/action of gut hormones such as GLP-1, GIP, leptin, and PYY triggered by direct stomach manipulation are responsible for the rapid restoration of insulin secretion and sensitivity (Yousseif et al., 2014). Ghrelin, released by the gastric fundus, which is normally excised during LSG (; Yang et al., 2015). Thus, decreased levels of ghrelin were also proposed to be one of the mechanisms that result in metabolic benefits following LSG. However, similar weight loss and improved glucose profile following LSG were found in ghrelin-deficient mice that was genetically modified compared to that in wild type mice (), suggesting that decreased ghrelin is not a critical factor in T2DM remission ().
In summary, glucose regulation after LSG seems to be partially medicated by the changes in gut hormones post-surgery and partially by the weight loss itself. The role of parasympathetic nervous system in regulating glucose homeostasis post-sleeve gastrectomy is less defined or data is lacking at least. It is more likely; however, that the parasympathetic nervous system is more involved (directly or indirectly) in changes in food intake behavior after LSG.
Conclusion
Bariatric surgery achieves sustainable improvements in treating metabolic dysfunction related to obesity and improves overall health. The underlying mechanisms by which these procedures cause weight loss and metabolic improvement appear to be diverse and are not yet fully identified. Current evidence suggests that the autonomic parasympathetic nervous system (mainly through its vagus arm) contributes to food intake reduction and improvements in glucose homeostasis following bariatric surgeries. The sympathetic nervous system is also altered after bariatric surgery, with human models showing decrease in systemic tone to the that might correlates with improvement in blood pressure and other homeostatic patterns. Rodent models of RYGB suggest a selective increase in the splanchnic sympathetic nerve activity of the gut, innervating the visceral fat and leading to augmented sympathetic-mediated thermogenesis. Future studies that further unfold details about the underlying molecular mechanisms communicating new energy signals from the gut to the brain along a neuro-hormonal pathway is essential to help us understand how this procedure induces its powerful metabolic effects. Development of effective and less-invasive therapies for weight-management (being surgical or pharmacological) would highly benefit from this information.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
MM conceptualized the idea and design of the review and critically revised the manuscript. ZA and HW wrote the first draft of the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by the VA Merit Review Program (I01 BX004774), The University of Iowa Department of Internal Medicine, and Fraternal Order of Eagles Diabetes Research Center.
Acknowledgments
We would like to thank Dr. Karim Noureddine for his critical revision of the manuscript’s language and grammatical context.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AhmedA. R.RickardsG.ConiglioD.XiaY.JohnsonJ.BossT.et al (2009). Laparoscopic Roux-en-Y gastric bypass and its early effect on blood pressure.Obes. Surg.19845–849. 10.1007/s11695-008-9671-z
2
AhrenB.WierupN.SundlerF. (2006). Neuropeptides and the regulation of islet function.Diabetes55S98–S107. 10.2337/db06-S013
3
AltschulerS. M.BaoX. M.BiegerD.HopkinsD. A.MiselisR. R. (1989). Viscerotopic representation of the upper alimentary tract in the rat: sensory ganglia and nuclei of the solitary and spinal trigeminal tracts.J. Comp. Neurol.283248–268. 10.1002/cne.902830207
4
BallsmiderL. A.VaughnA. C.DavidM.HajnalA.Di LorenzoP. M.CzajaK. (2015). Sleeve gastrectomy and Roux-en-Y gastric bypass alter the gut-brain communication.Neural Plast.2015:601985. 10.1155/2015/601985
5
BatterhamR. L.CummingsD. E. (2016). Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery.Diabetes Care39893–901. 10.2337/dc16-0145
6
BenaigesD.Mas-LorenzoA.GodayA.RamonJ. M.ChillaronJ. J.Pedro-BotetJ.et al (2015). Laparoscopic sleeve gastrectomy: more than a restrictive bariatric surgery procedure?World J. Gastroenterol.2111804–11814. 10.3748/wjg.v21.i41.11804
7
BerthoudH. R. (2008). Vagal and hormonal gut-brain communication: from satiation to satisfaction.Neurogastroenterol. Motil.2064–72. 10.1111/j.1365-2982.2008.01104.x
8
BerthoudH. R.CarlsonN. R.PowleyT. L. (1991). Topography of efferent vagal innervation of the rat gastrointestinal tract.Am. J. Physiol.260R200–R207. 10.1152/ajpregu.1991.260.1.R200
9
BerthoudH. R.PowleyT. L. (1992). Vagal afferent innervation of the rat fundic stomach: morphological characterization of the gastric tension receptor.J. Comp. Neurol.319261–276. 10.1002/cne.903190206
10
BerthoudH. R.ShinA. C.ZhengH. (2011). Obesity surgery and gut-brain communication.Physiol. Behav.105106–119. 10.1016/j.physbeh.2011.01.023
11
BoidoA.CerianiV.CettaF.LombardiF.PontiroliA. E. (2015). Bariatric surgery and prevention of cardiovascular events and mortality in morbid obesity: mechanisms of action and choice of surgery.Nutr. Metab. Cardiovasc. Dis.25437–443. 10.1016/j.numecd.2015.01.011
12
BorgeraasH.HofsoD.HertelJ. K.HjelmesaethJ. (2020). Comparison of the effect of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Obes. Rev.21:e13011. 10.1111/obr.13011
13
Borges MdeC.TerraG. A.TakeutiT. D.RibeiroB. M.SilvaA. A.Terra-JuniorJ. A.et al (2015). Immunological evaluation of patients with type 2 diabetes mellitus submitted to metabolic surgery.Arq. Bras. Cir. Dig.28266–269. 10.1590/s0102-6720201500040012
14
BradleyD.MagkosF.KleinS. (2012). Effects of bariatric surgery on glucose homeostasis and type 2 diabetes.Gastroenterology143897–912. 10.1053/j.gastro.2012.07.114
15
BroussardD. L.AltschulerS. M. (2000). Brainstem viscerotopic organization of afferents and efferents involved in the control of swallowing.Am. J. Med.10879S–86S. 10.1016/S0002-9343(99)00343-5
16
BrowningK. N.FortnaS. R.HajnalA. (2013). Roux-en-Y gastric bypass reverses the effects of diet-induced obesity to inhibit the responsiveness of central vagal motoneurones.J. Physiol.5912357–2372. 10.1113/jphysiol.2012.249268
17
CamposC. A.ShiinaH.SilvasM.PageS.RitterR. C. (2013). Vagal afferent NMDA receptors modulate CCK-induced reduction of food intake through synapsin I phosphorylation in adult male rats.Endocrinology1542613–2625. 10.1210/en.2013-1062
18
CamposC. A.WrightJ. S.CzajaK.RitterR. C. (2012). CCK-induced reduction of food intake and hindbrain MAPK signaling are mediated by NMDA receptor activation.Endocrinology1532633–2646. 10.1210/en.2012-1025
19
CardinalP.AndreC.QuartaC.BellocchioL.ClarkS.ElieM.et al (2014). CB1 cannabinoid receptor in SF1-expressing neurons of the ventromedial hypothalamus determines metabolic responses to diet and leptin.Mol. Metab.3705–716. 10.1016/j.molmet.2014.07.004
20
ChambersA. P.KirchnerH.Wilson-PerezH. E.WillencyJ. A.HaleJ. E.GaylinnB. D.et al (2013). The effects of vertical sleeve gastrectomy in rodents are ghrelin independent.Gastroenterology14450–52.e5. 10.1053/j.gastro.2012.09.009
21
ChambersA. P.SmithE. P.BeggD. P.GraysonB. E.SisleyS.GreerT.et al (2014). Regulation of gastric emptying rate and its role in nutrient-induced GLP-1 secretion in rats after vertical sleeve gastrectomy.Am. J. Physiol. Endocrinol. Metab.306E424–E432. 10.1152/ajpendo.00469.2013
22
ChingS. S.ChengA. K.KongL. W.LomantoD.SoJ. B.ShabbirA. (2016). Early outcomes of laparoscopic sleeve gastrectomy in a multiethnic Asian cohort.Surg. Obes. Relat. Dis.12330–337. 10.1016/j.soard.2015.05.009
23
ChoJ. M.KimH. J.Lo MenzoE.ParkS.SzomsteinS.RosenthalR. J. (2015). Effect of sleeve gastrectomy on type 2 diabetes as an alternative treatment modality to Roux-en-Y gastric bypass: systemic review and meta-analysis.Surg. Obes. Relat. Dis.111273–1280. 10.1016/j.soard.2015.03.001
24
CurryT. B.SomarajuM.HinesC. N.GroenewaldC. B.MilesJ. M.JoynerM. J.et al (2013). Sympathetic support of energy expenditure and sympathetic nervous system activity after gastric bypass surgery.Obesity21480–485. 10.1002/oby.20106
25
CzajaK.RitterR. C.BurnsG. A. (2006). Vagal afferent neurons projecting to the stomach and small intestine exhibit multiple N-methyl-D-aspartate receptor subunit phenotypes.Brain Res.111986–93. 10.1016/j.brainres.2006.08.042
26
de OliveiraL. F.TisottC. G.SilvanoD. M.CamposC. M.do NascimentoR. R. (2015). Glycemic behavior in 48 hours postoperative period of patients with type 2 diabetes mellitus and non diabetic submitted to bariatric surgery.Arq. Bras. Cir. Dig.2826–30. 10.1590/S0102-6720201500S100009
27
DiPatrizioN. V.AstaritaG.SchwartzG.LiX.PiomelliD. (2011). Endocannabinoid signal in the gut controls dietary fat intake.Proc. Natl. Acad. Sci. U. S. A.10812904–12908. 10.1073/pnas.1104675108
28
DochertyN. G.FandriksL.le RouxC. W.HallersundP.WerlingM. (2017). Urinary sodium excretion after gastric bypass surgery.Surg. Obes. Relat. Dis.131506–1514. 10.1016/j.soard.2017.04.002
29
EnglishW. J.DeMariaE. J.BrethauerS. A.MattarS. G.RosenthalR. J.MortonJ. M. (2018). American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016.Surg. Obes. Relat. Dis.14259–263. 10.1016/j.soard.2017.12.013
30
EnglishW. J.DeMariaE. J.HutterM. M.KothariS. N.MattarS. G.BrethauerS. A.et al (2020). American Society for Metabolic and Bariatric Surgery 2018 estimate of metabolic and bariatric procedures performed in the United States.Surg. Obes. Relat. Dis.16457–463. 10.1016/j.soard.2019.12.022
31
EslerM.LambertG.Brunner-La RoccaH. P.VaddadiG.KayeD. (2003). Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice.Acta Physiol. Scand.177275–284. 10.1046/j.1365-201X.2003.01089.x
32
FalkenY.HellstromP. M.HolstJ. J.NaslundE. (2011). Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides.J. Clin. Endocrinol. Metab.962227–2235. 10.1210/jc.2010-2876
33
FoxE. A.PhillipsR. J.MartinsonF. A.BaronowskyE. A.PowleyT. L. (2000). Vagal afferent innervation of smooth muscle in the stomach and duodenum of the mouse: morphology and topography.J. Comp. Neurol.428558–576. 10.1002/1096-9861(20001218)428:3<558::AID-CNE11>3.0.CO;2-M
34
GaetaniS.FuJ.CassanoT.DipasqualeP.RomanoA.RighettiL.et al (2010). The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin.J. Neurosci.308096–8101. 10.1523/JNEUROSCI.0036-10.2010
35
GallaherZ. R.RyuV.HerzogT.RitterR. C.CzajaK. (2012). Changes in microglial activation within the hindbrain, nodose ganglia, and the spinal cord following subdiaphragmatic vagotomy.Neurosci. Lett.51331–36. 10.1016/j.neulet.2012.01.079
36
GautronL. (2021). The Phantom satiation hypothesis of bariatric surgery.Front. Neurosci.15:626085. 10.3389/fnins.2021.626085
37
GeronikolouS. A.AlbanopoulosK.ChrousosG.CokkinosD. (2017). Evaluating the homeostasis assessment model insulin resistance and the cardiac autonomic system in bariatric surgery patients: a meta-analysis.Adv. Exp. Med. Biol.988249–259. 10.1007/978-3-319-56246-9_20
38
GrassiG.BiffiA.SeravalleG.TrevanoF. Q.Dell’OroR.CorraoG.et al (2019). Sympathetic neural overdrive in the obese and overweight state.Hypertension74349–358. 10.1161/HYPERTENSIONAHA.119.12885
39
GraysonB. E.FitzgeraldM. F.Hakala-FinchA. P.FerrisV. M.BeggD. P.TongJ.et al (2014). Improvements in hippocampal-dependent memory and microglial infiltration with calorie restriction and gastric bypass surgery, but not with vertical sleeve gastrectomy.Int. J. Obes.38349–356. 10.1038/ijo.2013.100
40
GuarinoD.NannipieriM.IervasiG.TaddeiS.BrunoR. M. (2017). The Role of the autonomic nervous system in the pathophysiology of obesity.Front. Physiol.8:665. 10.3389/fphys.2017.00665
41
HalesC. M.CarrollM. D.FryarC. D.OgdenC. L. (2020). Prevalence of obesity and severe obesity among adults: United States, 2017-2018.NCHS Data Brief3601–8.
42
HankirM. K.SeyfriedF.HintschichC. A.DiepT. A.KlebergK.KranzM.et al (2017). Gastric bypass surgery recruits a gut PPAR-alpha-striatal D1R pathway to reduce fat appetite in obese rats.Cell Metab.25335–344. 10.1016/j.cmet.2016.12.006
43
HaoZ.TownsendR. L.MumphreyM. B.PattersonL. M.YeJ.BerthoudH. R. (2014). Vagal innervation of intestine contributes to weight loss After Roux-en-Y gastric bypass surgery in rats.Obes. Surg.242145–2151. 10.1007/s11695-014-1338-3
44
HolzmanL. B.St JohnP. L.KovariI. A.VermaR.HolthoferH.AbrahamsonD. R. (1999). Nephrin localizes to the slit pore of the glomerular epithelial cell.Kidney Int.561481–1491. 10.1046/j.1523-1755.1999.00719.x
45
HuszarD.LynchC. A.Fairchild-HuntressV.DunmoreJ. H.FangQ.BerkemeierL. R.et al (1997). Targeted disruption of the melanocortin-4 receptor results in obesity in mice.Cell88131–141. 10.1016/S0092-8674(00)81865-6
46
HutchC. R.SandovalD. (2017). The Role of GLP-1 in the Metabolic Success of Bariatric Surgery.Endocrinology1584139–4151. 10.1210/en.2017-00564
47
IbacacheP.CarcamoP.MirandaC.BottinelliA.GuzmanJ.Martinez-RosalesE.et al (2020). Improvements in heart rate variability in women with obesity: short-term effects of sleeve gastrectomy.Obes. Surg.304038–4045. 10.1007/s11695-020-04721-y
48
JorgensenN. B.JacobsenS. H.DirksenC.Bojsen-MollerK. N.NaverL.HvolrisL.et al (2012). Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance.Am. J. Physiol. Endocrinol. Metab.303E122–E131. 10.1152/ajpendo.00073.2012
49
KamiyaA.HiyamaT.FujimuraA.YoshikawaS. (2021). Sympathetic and parasympathetic innervation in cancer: therapeutic implications.Clin. Auton. Res.31165–178. 10.1007/s10286-020-00724-y
50
KatsogiannosP.KambleP. G.WiklundU.SundbomM.EspesD.HammarU.et al (2020). Rapid changes in neuroendocrine regulation may contribute to reversal of type 2 diabetes after gastric bypass surgery.Endocrine67344–353. 10.1007/s12020-020-02203-w
51
KirchgessnerA. L.GershonM. D. (1989). Identification of vagal efferent fibers and putative target neurons in the enteric nervous system of the rat.J. Comp. Neurol.28538–53. 10.1002/cne.902850105
52
LandsbergL. (1986). Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis.Q. J. Med.611081–1090.
53
LandsbergL. (2001). Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why).J. Hypertens.19523–528. 10.1097/00004872-200103001-00001
54
LarabeeC. M.NeelyO. C.DomingosA. I. (2020). Obesity: a neuroimmunometabolic perspective.Nat. Rev. Endocrinol.1630–43. 10.1038/s41574-019-0283-6
55
le RouxC. W.WelbournR.WerlingM.OsborneA.KokkinosA.LaureniusA.et al (2007). Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass.Ann. Surg.246780–785. 10.1097/SLA.0b013e3180caa3e3
56
LinB. Y.LinW. D.HuangC. K.HsinM. C.LinW. Y.PryorA. D. (2019). Changes of gut microbiota between different weight reduction programs.Surg. Obes. Relat. Dis.15749–758. 10.1016/j.soard.2019.01.026
57
LiouA. P.PaziukM.LuevanoJ. M.Jr.MachineniS.TurnbaughP. J.KaplanL. M. (2013). Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity.Sci. Transl. Med.5:178ra41. 10.1126/scitranslmed.3005687
58
LipsM. A.de GrootG. H.De KamM.BerendsF. J.WiezerR.Van WagensveldB. A.et al (2013). Autonomic nervous system activity in diabetic and healthy obese female subjects and the effect of distinct weight loss strategies.Eur. J. Endocrinol.169383–390. 10.1530/EJE-13-0506
59
LohmeierT. E.IliescuR. (2013). The sympathetic nervous system in obesity hypertension.Curr. Hypertens. Rep.15409–416. 10.1007/s11906-013-0356-1
60
MaserR. E.LenhardM. J.IrgauI.WynnG. M. (2007). Impact of surgically induced weight loss on cardiovascular autonomic function: one-year follow-up.Obesity15364–369. 10.1038/oby.2007.554
61
McCrackenJ.SteinbeisserM.KharbutliB. (2018). Does size matter? correlation of excised gastric specimen size in sleeve gastrectomy to postoperative weight loss and comorbidities.Obes. Surg.281002–1006. 10.1007/s11695-017-2975-0
62
McGaviganA. K.HenselerZ. M.GaribayD.ButlerS. D.JayasingheS.LeyR. E.et al (2017). Vertical sleeve gastrectomy reduces blood pressure and hypothalamic endoplasmic reticulum stress in mice.Dis. Model. Mech.10235–243. 10.1242/dmm.027474
63
McTigueK. M.WellmanR.NaumanE.AnauJ.ColeyR. Y.OdorA.et al (2020). Comparing the 5-Year diabetes outcomes of sleeve gastrectomy and gastric bypass: the national patient-centered clinical research network (PCORNet) bariatric study.JAMA Surg.155:e200087. 10.1001/jamasurg.2020.0087
64
MingroneG.CummingsD. E. (2016). Changes of insulin sensitivity and secretion after bariatric/metabolic surgery.Surg. Obes. Relat. Dis.121199–1205. 10.1016/j.soard.2016.05.013
65
MingroneG.PanunziS.De GaetanoA.GuidoneC.IaconelliA.NanniG.et al (2015). Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.Lancet386964–973. 10.1016/S0140-6736(15)00075-6
66
MoranT. H.BaldessariniA. R.SalorioC. F.LoweryT.SchwartzG. J. (1997). Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin.Am. J. Physiol.272R1245–R1251. 10.1152/ajpregu.1997.272.4.R1245
67
MullaC. M.MiddelbeekR. J. W.PattiM. E. (2018). Mechanisms of weight loss and improved metabolism following bariatric surgery.Ann. N. Y. Acad. Sci.141153–64. 10.1111/nyas.13409
68
O’BrienP. E. (2015). Controversies in bariatric surgery.Br. J. Surg.102611–618. 10.1002/bjs.9760
69
OchnerC. N.GibsonC.ShanikM.GoelV.GeliebterA. (2011). Changes in neurohormonal gut peptides following bariatric surgery.Int. J. Obes.35153–166. 10.1038/ijo.2010.132
70
OdstrcilE. A.MartinezJ. G.Santa AnaC. A.XueB.SchneiderR. E.StefferK. J.et al (2010). The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass.Am. J. Clin. Nutr.92704–713. 10.3945/ajcn.2010.29870
71
OkaforP. N.LienC.BairdainS.SimonsonD. C.HalperinF.VernonA. H.et al (2015). Effect of vagotomy during Roux-en-Y gastric bypass surgery on weight loss outcomes.Obes. Res. Clin. Pract.9274–280. 10.1016/j.orcp.2014.09.005
72
PalmenT.AholaH.PalgiJ.AaltonenP.LuimulaP.WangS.et al (2001). Nephrin is expressed in the pancreatic beta cells.Diabetologia441274–1280. 10.1007/s001250100641
73
ParikhM.IssaR.McCrillisA.SaundersJ. K.Ude-WelcomeA.GagnerM. (2013). Surgical strategies that may decrease leak after laparoscopic sleeve gastrectomy: a systematic review and meta-analysis of 9991 cases.Ann. Surg.257231–237. 10.1097/SLA.0b013e31826cc714
74
ParlevlietE. T.de Leeuw van WeenenJ. E.RomijnJ. A.PijlH. (2010). GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet.Am. J. Physiol. Endocrinol. Metab.299E318–E324. 10.1152/ajpendo.00191.2010
75
PeruginiR. A.LiY.RosenthalL.Gallagher-DorvalK.KellyJ. J.CzerniachD. R. (2010). Reduced heart rate variability correlates with insulin resistance but not with measures of obesity in population undergoing laparoscopic Roux-en-Y gastric bypass.Surg. Obes. Relat. Dis.6237–241. 10.1016/j.soard.2009.09.012
76
PetersJ. H.GallaherZ. R.RyuV.CzajaK. (2013). Withdrawal and restoration of central vagal afferents within the dorsal vagal complex following subdiaphragmatic vagotomy.J. Comp. Neurol.5213584–3599. 10.1002/cne.23374
77
PetersJ. H.McKayB. M.SimaskoS. M.RitterR. C. (2005). Leptin-induced satiation mediated by abdominal vagal afferents.Am. J. Physiol. Regul. Integr. Comp. Physiol.288R879–R884. 10.1152/ajpregu.00716.2004
78
PournarasD. J.le RouxC. W. (2013). Are bile acids the new gut hormones? Lessons from weight loss surgery models.Endocrinology1542255–2256. 10.1210/en.2013-1383
79
PowleyT. L.PhillipsR. J. (2002). Musings on the wanderer: what’s new in our understanding of vago-vagal reflexes? I. Morphology and topography of vagal afferents innervating the GI tract.Am. J. Physiol. Gastrointest. Liver Physiol.283G1217–G1225. 10.1152/ajpgi.00249.2002
80
PrechtlJ. C.PowleyT. L. (1990). The fiber composition of the abdominal vagus of the rat.Anat. Embryol.181101–115. 10.1007/BF00198950
81
QiuN. C.ZhangQ.SongX.LiuM. E.LiX. K.ShanC. X.et al (2014). Impact of the hepatic branch of the vagus and Roux-en-Y gastric bypass on the hypoglycemic effect and glucagon-like peptide-1 in rats with type 2 diabetes mellitus.J. Surg. Res.191123–129. 10.1016/j.jss.2014.03.062
82
QuartaC.BellocchioL.ManciniG.MazzaR.CervinoC.BraulkeL. J.et al (2010). CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance.Cell Metab.11273–285. 10.1016/j.cmet.2010.02.015
83
RamonJ. M.SalvansS.CrousX.PuigS.GodayA.BenaigesD.et al (2012). Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial.J. Gastrointest. Surg.161116–1122. 10.1007/s11605-012-1855-0
84
RaynerD. V.TrayhurnP. (2001). Regulation of leptin production: sympathetic nervous system interactions.J. Mol. Med.798–20. 10.1007/s001090100198
85
RodriguezA.BecerrilS.ValentiV.MoncadaR.Mendez-GimenezL.RamirezB.et al (2012). Short-term effects of sleeve gastrectomy and caloric restriction on blood pressure in diet-induced obese rats.Obes. Surg.221481–1490. 10.1007/s11695-012-0702-4
86
RosenthalR. J.International Sleeve Gastrectomy Expert Panel, DiazA. A.ArvidssonD.BakerR. S.BassoN. (2012). International Sleeve Gastrectomy Expert Panel Consensus Statement: best practice guidelines based on experience of >12,000 cases.Surg. Obes. Relat. Dis.88–19. 10.1016/j.soard.2011.10.019
87
SaeidiN.NestoridiE.KucharczykJ.UygunM. K.YarmushM. L.StylopoulosN. (2012). Sleeve gastrectomy and Roux-en-Y gastric bypass exhibit differential effects on food preferences, nutrient absorption and energy expenditure in obese rats.Int. J. Obes.361396–1402. 10.1038/ijo.2012.167
88
SalehiM.PrigeonR. L.D’AlessioD. A. (2011). Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans.Diabetes602308–2314. 10.2337/db11-0203
89
SchauerP. R.BhattD. L.KashyapS. R. (2017). Bariatric surgery or intensive medical therapy for diabetes after 5 Years.N. Engl. J. Med.376:1997. 10.1056/NEJMc1703377
90
SchauerP. R.KashyapS. R.WolskiK.BrethauerS. A.KirwanJ. P.PothierC. E.et al (2012). Bariatric surgery versus intensive medical therapy in obese patients with diabetes.N. Engl. J. Med.3661567–1576. 10.1056/NEJMoa1200225
91
SeravalleG.ColomboM.PeregoP.GiardiniV.VolpeM.Dell’OroR.et al (2014). Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients.Hypertension64431–437. 10.1161/HYPERTENSIONAHA.113.02988
92
SjostromL.PeltonenM.JacobsonP.SjostromC. D.KarasonK.WedelH.et al (2012). Bariatric surgery and long-term cardiovascular events.JAMA30756–65. 10.1001/jama.2011.1914
93
SmithE. P.AnZ.WagnerC.LewisA. G.CohenE. B.LiB.et al (2014). The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs.Cell Metab.191050–1057. 10.1016/j.cmet.2014.04.005
94
StefaterM. A.Wilson-PerezH. E.ChambersA. P.SandovalD. A.SeeleyR. J. (2012). All bariatric surgeries are not created equal: insights from mechanistic comparisons.Endocr. Rev.33595–622. 10.1210/er.2011-1044
95
SterlK.WangS.OestrickerL.WallendorfM. J.PattersonB. W.ReedsD. N.et al (2016). Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery.Peptides8276–84. 10.1016/j.peptides.2016.06.001
96
TellezL. A.MedinaS.HanW.FerreiraJ. G.Licona-LimonP.RenX.et al (2013). A gut lipid messenger links excess dietary fat to dopamine deficiency.Science341800–802. 10.1126/science.1239275
97
Ten KulveJ. S.VeltmanD. J.GerdesV. E. A.van BloemendaalL.BarkhofF.DeaconC. F.et al (2017). Elevated postoperative endogenous GLP-1 levels mediate effects of roux-en-Y gastric bypass on neural responsivity to food cues.Diabetes Care401522–1529. 10.2337/dc16-2113
98
TopartP.BecouarnG.RitzP. (2011). Pouch size after gastric bypass does not correlate with weight loss outcome.Obes. Surg.211350–1354. 10.1007/s11695-011-0460-8
99
TremblayA.ChaputJ. P. (2009). Adaptive reduction in thermogenesis and resistance to lose fat in obese men.Br. J. Nutr.102488–492. 10.1017/S0007114508207245
100
TritschA. M.BlandC. M.HatzigeorgiouC.SweeneyL. B.PhillipsM. (2015). A retrospective review of the medical management of hypertension and diabetes mellitus following sleeve gastrectomy.Obes. Surg.25642–647. 10.1007/s11695-014-1375-y
101
VaisseC.ClementK.Guy-GrandB.FroguelP. (1998). A frameshift mutation in human MC4R is associated with a dominant form of obesity.Nat. Genet.20113–114. 10.1038/2407
102
WaddenT. A.WebbV. L.MoranC. H.BailerB. A. (2012). Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy.Circulation1251157–1170. 10.1161/CIRCULATIONAHA.111.039453
103
WalleniusV.DirinckE.FandriksL.MaleckasA.le RouxC. W.ThorellA. (2018). Glycemic Control after Sleeve Gastrectomy and Roux-En-Y Gastric Bypass in Obese Subjects with Type 2 Diabetes Mellitus.Obes. Surg.281461–1472. 10.1007/s11695-017-3061-3
104
WangY. C.McPhersonK.MarshT.GortmakerS. L.BrownM. (2011). Health and economic burden of the projected obesity trends in the USA and the UK.Lancet378815–825. 10.1016/S0140-6736(11)60814-3
105
WasmundS. L.OwanT.YanowitzF. G.AdamsT. D.HuntS. C.HamdanM. H.et al (2011). Improved heart rate recovery after marked weight loss induced by gastric bypass surgery: two-year follow up in the Utah Obesity Study.Heart Rhythm884–90. 10.1016/j.hrthm.2010.10.023
106
WilliamsS. M.EleftheriadouA.AlamU.CuthbertsonD. J.WildingJ. P. H. (2019). Cardiac autonomic neuropathy in obesity, the metabolic syndrome and prediabetes: a narrative review.Diabetes Ther.101995–2021. 10.1007/s13300-019-00693-0
107
Wilson-PerezH. E.ChambersA. P.RyanK. K.LiB.SandovalD. A.StoffersD.et al (2013). Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency.Diabetes622380–2385. 10.2337/db12-1498
108
YanW.PolidoriD.YiehL.DiJ.WuX.MorenoV.et al (2014). Effects of meal size on the release of GLP-1 and PYY after Roux-en-Y gastric bypass surgery in obese subjects with or without type 2 diabetes.Obes. Surg.241969–1974. 10.1007/s11695-014-1316-9
109
YangJ.WangC.CaoG.YangW.YuS.ZhaiH.et al (2015). Long-term effects of laparoscopic sleeve gastrectomy versus roux-en-Y gastric bypass for the treatment of Chinese type 2 diabetes mellitus patients with body mass index 28-35 kg/m(2).BMC Surg.15:88. 10.1186/s12893-015-0074-5
110
YeY.Abu El HaijaM.MorganD. A.GuoD.SongY.FrankA. (2020). Endocannabinoid receptor-1 and sympathetic nervous system mediate the beneficial metabolic effects of gastric bypass.Cell Rep.33:108270. 10.1016/j.celrep.2020.108270
111
YousseifA.EmmanuelJ.KarraE.MilletQ.ElkalaawyM.JenkinsonA. D.et al (2014). Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans.Obes. Surg.24241–252. 10.1007/s11695-013-1066-0
112
ZechnerJ. F.MirshahiU. L.SatapatiS.BerglundE. D.RossiJ.ScottM. M.et al (2013). Weight-independent effects of roux-en-Y gastric bypass on glucose homeostasis via melanocortin-4 receptors in mice and humans.Gastroenterology144580–590.e7. 10.1053/j.gastro.2012.11.022
113
ZhangH.PuY.ChenJ.TongW.CuiY.SunF.et al (2014). Gastrointestinal intervention ameliorates high blood pressure through antagonizing overdrive of the sympathetic nerve in hypertensive patients and rats.J. Am. Heart Assoc.3:e000929. 10.1161/JAHA.114.000929
Summary
Keywords
parasympathetic nervous system, sympathetic nervous system, energy balance, metabolic regulation, bariatric/metabolic surgery
Citation
An Z, Wang H and Mokadem M (2021) Role of the Autonomic Nervous System in Mechanism of Energy and Glucose Regulation Post Bariatric Surgery. Front. Neurosci. 15:770690. doi: 10.3389/fnins.2021.770690
Received
04 September 2021
Accepted
15 October 2021
Published
23 November 2021
Volume
15 - 2021
Edited by
Lionel Carneiro, The Ohio State University, United States
Reviewed by
Yves Borbély, Bern University Hospital, Switzerland; Marcellino Monda, Università degli Studi della Campania Luigi Vanvitelli, Italy
Updates
Copyright
© 2021 An, Wang and Mokadem.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mohamad Mokadem, mohamad-mokadem@uiowa.edu
†These authors have contributed equally to this work
This article was submitted to Neuroenergetics, Nutrition and Brain Health, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.